Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vibsanin A, an activator of protein kinase C (PKC) and an inhibitor of HSP90, demonstrates anti-proliferative effects on human cancer cell lines.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | Vibsanin A, an activator of protein kinase C (PKC) and an inhibitor of HSP90, demonstrates anti-proliferative effects on human cancer cell lines. |
In vitro | LDCA (2-100 μM ; 16-72 h) and Doxorubicin combination synergistically inhibit tumor progression. 15% death when cells were exposed to LDCA individually and caused 40% melanoma cell death combination synergistically with doxorubicin.[1] |
In vivo | LDA (2 mg/kg, iv., 6 days ; once) combination with doxorubicin effectively alleviated tumor necrosis in mice and significantly improved their survival ability, leading to sustained limitations in tumor growth kinetics.[1] |
分子量 | 402.57 |
分子式 | C25H38O4 |
CAS No. | 72506-14-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vibsanin A 72506-14-0 Inhibitor inhibitor inhibit